본문 바로가기

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
DRUG DESIGN DEVELOPMENT AND THERAPY12 · pp.2467 · 2018
피인용
Web of Science 8Scopus 8
FWCI (Scopus)
0.64
JCR IF
JCR 2017 2.935
ISSN
1177-8881

저자

  1. 조은아제1저자Department of Pharmacology and Medical Research Center (MRC), Pusan National University School of Medicine, Yangsan, South Korea
  2. Ryu, Eun JinDepartment of Radiology, Pusan National University Yangsan Hospital, Yangsan, South Korea
  3. Jiang, FenDepartment of Research and Development, Bionoxx Inc, South Korea
  4. 전웅배Department of Radiology, Pusan National University Yangsan Hospital, Yangsan, South Korea
  5. 조몽Department of Pharmacology and Medical Research Center (MRC), Pusan National University School of Medicine, Yangsan, South Korea
  6. 김시현Department of Pharmacology and Medical Research Center (MRC), Pusan National University School of Medicine, Yangsan, South Korea
  7. 김미영Department of Pharmacology and Medical Research Center (MRC), Pusan National University School of Medicine, Yangsan, South Korea
  8. 김남득Department of Pharmacy and Pusan Cancer Research Center, Pusan National University, Busan, South Korea
  9. 황태호교신저자Department of Pharmacology and Medical Research Center (MRC), Pusan National University School of Medicine, Yangsan, South Korea

초록

Purpose: Oncolytic poxvirus lias shown promise in treating various solid tumors, such as liver cancer, and administration of oncolytic poxvirus via the hepatic artery may provide more survival benefits than other routes of administration. However, there is a lack of safety information to guide the application ofhepatic arterial infusion (HAI) of oncolytic poxvirus in human studies. To investigate the acute and chronic toxicity of HAI administration of oncolytic poxvirus in animals and provide safety information for future human studies. Methods: VVtk-, a vaccinia poxvirus with inactivated thymidine kinase gene, was administered via HAI to rabbits with normal liver function under angiography (1x10(8) or 1x10(9) pfu), and rats with N-nitrosomorpholine-induced precancerous liver cirrhosis under open surgery (1x10(8) pfu). Body weights and survival were monitored and blood samples were collected for hematological and biochemical tests. Distribution of A56 (a specific marker for poxvirus infection) in rabbit organs was evaluated using immunofluorescence assays. Results: HAI ofhigh doses of VVtk- did not cause any acute or chronic changes in body weight, survival or in biochemical, hematological tests in the 2 animal models, and none of the changes showed dose dependency (in rabbit study), or were influenced by liver cirrhosis (in rat study). A56 was not detected in any of the major rabbit organs. Conclusion: HAI may provide a safe alternative route of oncolytic poxvirus administration for human studies.

키워드

oncolytic virustranshepatic angiographyhepatocellular carcinomaliver cirrhosisCOLORECTAL LIVER METASTASESHEPATOCELLULAR-CARCINOMAVIRUSTHERAPYCANCERPROTEINSSURVIVALJX-594TRIAL

식별자

Scopus EID
2-s2.0-85057214031
WoS UID
000441176800001